Intellectual Property - May 25, 2022
Ilya Pharma extends global patent coverage
Ilya Pharma has announced that the Indian Patent Office (IPO) has issued the Company Patent titled “Methods for Wound Healing”. The patent covers the general use of a plasmid capable of expressing the protein CXCL12 in L. reuteri. The modified bacteria may be used for treatment of both mucosal and cutaneous wounds in humans and […]
In a new job - May 5, 2022
Ilya Pharma appoints corporate development specialists
Ilya Pharma has announced the appointments of Dr Melya Hughes Crameri and William (Bill) Carson to the Board of Directors. The appointments come as the company approaches key stages in the development of its portfolio of three immunotherapies for skin and mucosal diseases, it states. “I am delighted to welcome Melya and Bill to the […]
Biotech Business - May 4, 2022
Ilya Pharma announces FDA clearance of IND
Ilya Pharma has announced that FDA have cleared an IND for its lead candidate ILP100-Topical and that the company is immediately accelerating preparations for large adaptive Phase 2 study, designed as a trial. ILP100-Topical is an immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes and obesity. These patients have weeks to months […]
Acquisition - April 20, 2022
Ilya Pharma makes strategic investment in bioanalytical company
Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis. Founded in 2010, Nordic Bioanalysis have established a strong reputation both in the Nordics and internationally as experts in bioanalytical development and validation for pharmaceuticals, classic small molecules […]
Biotech Business - March 17, 2022
Ilya Pharma closes 8.5 million EUR funding round
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors. “I believe Ilya is at the forefront of science by developing what can be the next advancement in biologics, tissue regeneration and immunology. The management’s decision to […]
Clinical Trials - January 12, 2022
Ilya Pharma to submit an IND for a Phase 1/2a study
Ilya Pharma is planning to submit an Investigational New Drug Application (IND) for a Phase 1/2a safety and dose finding clinical study of ILP100-Oral, the company’s investigational immunotherapy being developed for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors. “Immune checkpoint inhibitors (ICI’s) have provided a welcome new front line range […]
